Corporate Finance

154
Corporate Finance

Glaxo

Ranbaxy

Cipla

Sun

DRL

2001

2000

2001

2000

2001

2000

2001

2000

2001

2000

ProfitabilityEBDIT/total assets

21.81

19.59

13.25

14.3

31.44

30.17

31.42

24.42

33.07

16.9

(percent)

EBIT/total assets

18.11

16.71

11.08

11.98

29.48

28.02

28.39

21.44

27.71

14.61

(percent)

PAT/net worth

14.54

13.39

7.85

8.47

27.06

25.89

32.27

24.29

34.62

16.76

Growth percent(Net) sales growth

18.3

6

23.55

6.92

39.2

18

13.67

32.6

110.3

15

(percent)

Total assets

30.93

11.36

4.63

5.81

31.64

23.57

21.82

8.23

58.09

16.77

Debt (long term)

–45

4.9

–45

196

–7

N.A.

–75.8

N.A.

317

N.A.

Equity (net worth)

42

9.4

–1

3.3

26

N.A.

27

N.A.

20.3

N.A.

PBT

38

0

4.7

–7

35

N.A.

61

N.A.

163

N.A.

PAT

37

–8

–2

–6.8

31.5

N.A.

63

N.A.

140

N.A.

MiscellaneousCurrent assets/

total assets

0.52

0.63

0.59

0.59

0.7

0.69

0.55

0.38

0.56

0.44

No. of shares

74,475,000

59,775,000

115,895,478

115,895,478

59,972,343

46,774,537

46,756,018

76,515,948

31,588,780

Dividend rate

55

50

100

75

45

0

50

0

40

5

(percent)

Price (Rs)

287.7

672.2

1043

538

1272

Exhibit 7.7 contd.